Injective price prediction: $4.52 support in focus as INJ slides 7.32%

Traders Union
All News
Crypto News
Injective drops 7.32% to $4.57 today

Highlights

Injective burned over $196,000 of INJ tokens in May's Community BuyBack, further reducing circulating supply and tightening availability.
Native USDC integration, U.S.-regulated INJ futures, and a Republic partnership expanded ecosystem utility, but price action remains under selling pressure.
Technicals show INJ trading just below immediate resistance at $4.68, with high volatility and a likely continuation of sideways-to-bearish action in the $4.52–$4.68 range.

Supply constraints intensify as buyback and partnerships reshape outlook

Injective’s monthly Community BuyBack on May 6, 2026, resulted in the burning of over $196,000 in INJ, representing a confirmed reduction in circulating supply that mechanically tightens near-term availability. Recent launches of native USDC and the first CFTC-regulated INJ futures in the U.S., alongside a record token burn and the ongoing impact of the Supply Squeeze Upgrade, have contributed to persistent supply constraint and increased utility within the ecosystem. The new partnership with Republic enables retail users to access pre-IPO shares, potentially expanding platform engagement, though price action has remained under broader selling pressure.

Mixed momentum signals as price tests intraday lows under resistance

On the technical front, the SMA-20, SMA-50, and SMA-200 are situated at $4.17, $3.53, and $4.36, respectively, while the Ichimoku Kijun (D1) acts as immediate resistance at $4.68. The daily MACD and ADX present a buy configuration, with CCI also in bullish territory; however, the RSI is elevated and Stoch RSI points to oversold conditions, producing a mixed momentum signal. Bull/Bear Power (BBP) is currently at 0.47 with a buy forecast, suggesting ongoing attempts by buyers to regain dominance, but the Awesome Oscillator remains neutral and offers no clear trend reinforcement. Today's price action opened at $4.56, below the previous close, forming a gap down and trading near the lower boundary of the intraday range ($4.52–$4.68), with moderate to high volatility. Divergent oscillators and recent downward pressure suggest potential for a short-term reversal if buyers increase activity.

Sideways outlook as entrenched bearish indicators limit upside

Looking ahead to the coming week, INJ is expected to trade within the $4.52–$4.68 range, reflecting a typical volatility band relative to current levels. The probability of an upward price move is low, estimated at less than 20%, as all weekly trend indicators (MA-50, RSI, ADX, and MACD) continue to signal bearishness. The central scenario remains for sideways movement in this corridor. A bullish scenario would require a sustained break above the $4.68 resistance, whereas a close below $4.52 would set the stage for further downside.

Anton Kharitonov, expert at Traders Union, believes that INJ fundamentals remain strong due to continued supply reductions and positive network developments. However, he sees price action under clear selling pressure, with technical signals giving a mixed, mostly defensive outlook. Until buyers reclaim resistance at $4.68, the base scenario remains sideways to weak. "I remain cautious: unless $4.68 is broken, downside risk prevails and INJ lacks a bullish catalyst this week."

Earlier, analysts noted that Injective’s technical outlook was constrained by persistent bearish pressure despite signs of short-term consolidation. The current environment not only reinforces that cautious stance but also highlights increased supply-side dynamics and ecosystem expansion, positioning the $4.68 resistance as a decisive level for any potential bullish reversal in the coming sessions.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.